Back to search

Article

Efficacy of immunochemotherapy compared with platinum-based chemotherapy and immunotherapy after tyrosine kinase inhibitor failure in advanced non-small cell lung cancer patients with EGFR mutation

2022-05-05

Abstract excerpt

<h4>Background: </h4> Patients with epidermal growth factor receptor ( EGFR )-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. We examined the efficacy of immunochemotherapy in actual clinical practice and investigated subgroups of EGFR -mutant patients suitable for immunochemotherapy. <h4>Methods: </h4> We...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cce54f05-b779-5360-9dcd-c67ef5dc545a
DOI
10.21203/rs.3.rs-1590589/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of immunochemotherapy compared with platinum-based chemotherapy and immunotherapy after tyrosine kinase inhibitor failure in advanced non-small cell lung cancer patients with EGFR mutationDOI 10.21203/rs.3.rs-1590589/v1
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.Semantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Efficacy of atezolizumab, bevacizumab, carboplatin, and paclitaxel for epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after tyrosine kinase inhibitor failure.Semantic proximity
Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance.Semantic proximity
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.Semantic proximity
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs.Semantic proximity
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity
Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.Semantic proximity
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.Semantic proximity
Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsSemantic proximity
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.Semantic proximity
Select a neighboring publication to make it the new centre.